The repeatable battery for the assessment of neuropsychological status (RBANS) and substance use disorders: a systematic review.

Kristoffer H��iland, Rune Raudeberg, Jens Egeland
Author Information
  1. Kristoffer H��iland: Sykehuset i Vestfold HF, Hospital Trust, Vestfold T��nsberg, 2168, 3103, Norway. krihoi@siv.no. ORCID
  2. Rune Raudeberg: Faculty of Psychology, University of Bergen, Bergen, Norway. ORCID
  3. Jens Egeland: Division of Mental Health and Addiction, Vestfold Hospital Trust, 2168, T��nsberg, Vestfold, 3103, Norway. jens.egeland@siv.no. ORCID

Abstract

BACKGROUND: Cognitive deficits are prevalent among substance use disorder (SUD) patients and affect treatment retention and outcome. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a well-researched instrument in diverse patient groups and has the potential to serve as an effective and accurate method for identifying cognitive impairment in SUD patients. This systematic review examines the RBANS' ability to detect cognitive impairment in SUD patients. Limitations of knowledge and the need for further research are discussed.
METHODS: We conducted a systematic search using PsycINFO, Medline, and Cochrane databases to identify relevant studies and articles on applying RBANS in SUD. No time limits were imposed on the search. Search words were RBANS, substance use disorder, drug use disorder, and alcohol use disorder, and the most common specific types of drugs (e.g., opiates, cannabis, and methamphetamine).
RESULTS: A systematic search identified 232 articles, of which 17 were found eligible and included in the review. Most studies examined patient groups using either alcohol, methamphetamine, or opioids. The results are presented in the form of a narrative review. We identified some evidence that the RBANS can detect group differences between SUD patients and healthy controls, but the findings were somewhat inconsistent. The literature search revealed little information about cognitive profiles, reliability, factor structure, and construct and criterion validity.
CONCLUSIONS: The evidence concerning the validity and usefulness of the RBANS in SUD populations is scarce. Future research should investigate cognitive profiles, reliability, factor structure, and construct and criterion validity.

Keywords

References

  1. Front Psychol. 2019 Nov 28;10:2636 [PMID: 31849759]
  2. J Int Neuropsychol Soc. 2022 Aug;28(7):756-779 [PMID: 34433502]
  3. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Dec 20;119:110611 [PMID: 35907518]
  4. Clin Psychol Rev. 2013 Dec;33(8):1010-24 [PMID: 24029221]
  5. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jul 13;117:110543 [PMID: 35257830]
  6. J Subst Abuse Treat. 2016 Jul;66:1-8 [PMID: 27211990]
  7. Appl Neuropsychol Adult. 2022 Nov-Dec;29(6):1511-1521 [PMID: 33831338]
  8. Drug Alcohol Depend. 2003 Aug 20;71(2):207-11 [PMID: 12927659]
  9. Arch Clin Neuropsychol. 2016 May;31(3):206-30 [PMID: 26984127]
  10. Appl Neuropsychol Adult. 2021 Nov-Dec;28(6):752-760 [PMID: 31841036]
  11. Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109130 [PMID: 34773776]
  12. Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1479-1500 [PMID: 27670676]
  13. BMC Psychiatry. 2022 Jun 21;22(1):414 [PMID: 35729547]
  14. J Psychiatr Res. 1975 Nov;12(3):189-98 [PMID: 1202204]
  15. Drug Alcohol Rev. 2019 May;38(4):435-442 [PMID: 30916448]
  16. J Psychiatr Res. 2022 Sep;153:182-188 [PMID: 35820226]
  17. Front Psychiatry. 2021 Jan 21;11:598835 [PMID: 33551868]
  18. Arch Clin Neuropsychol. 2017 Jun 1;32(4):491-498 [PMID: 28334244]
  19. Exp Clin Psychopharmacol. 2009 Oct;17(5):337-44 [PMID: 19803633]
  20. Psychiatry Res. 2004 Nov 30;129(1):45-53 [PMID: 15572184]
  21. Drug Alcohol Rev. 2013 Jul;32(4):381-8 [PMID: 23240781]
  22. Percept Mot Skills. 2023 Oct;130(5):1970-1984 [PMID: 37380620]
  23. Front Psychiatry. 2020 Sep 11;11:00694 [PMID: 33061908]
  24. J Clin Exp Neuropsychol. 2018 Mar;40(2):107-122 [PMID: 28436744]
  25. Subst Use Misuse. 2018 May 12;53(6):881-890 [PMID: 29293037]
  26. Hum Psychopharmacol. 2009 Oct;24(7):524-31 [PMID: 19650155]
  27. Alcohol Clin Exp Res. 2017 Aug;41(8):1432-1443 [PMID: 28618018]
  28. Addiction. 2017 May;112(5):751-757 [PMID: 27535787]
  29. CNS Spectr. 2019 Feb;24(1):102-113 [PMID: 30591083]
  30. Exp Clin Psychopharmacol. 1997 Feb;5(1):39-50 [PMID: 9234038]
  31. Schizophr Res. 2004 Oct 1;70(2-3):175-86 [PMID: 15329294]
  32. Neuropsychol Rev. 2013 Jun;23(2):117-37 [PMID: 23129391]
  33. J Clin Psychopharmacol. 2015 Oct;35(5):517-24 [PMID: 26280836]
  34. Neuropsychol Rev. 2013 Mar;23(1):27-47 [PMID: 23412885]
  35. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9 [PMID: 9845158]
  36. Dialogues Clin Neurosci. 2019 Sep;21(3):281-290 [PMID: 31749652]
  37. Addict Biol. 2013 Mar;18(2):203-13 [PMID: 22264351]
  38. Front Psychiatry. 2014 Jul 16;5:78 [PMID: 25076914]
  39. J Stud Alcohol. 2006 Sep;67(5):685-93 [PMID: 16847536]
  40. J Am Geriatr Soc. 2005 Apr;53(4):695-9 [PMID: 15817019]
  41. Medicine (Baltimore). 2017 Apr;96(15):e6582 [PMID: 28403087]
  42. Addict Biol. 2016 Jul;21(4):873-84 [PMID: 25678237]
  43. Front Psychiatry. 2023 May 25;14:1156149 [PMID: 37304431]
  44. Arch Clin Neuropsychol. 2013 Dec;28(8):837-44 [PMID: 23867976]
  45. Appl Neuropsychol Adult. 2023 Jun 4;:1-12 [PMID: 37272014]
  46. J Psychopharmacol. 2010 Sep;24(9):1317-32 [PMID: 20007413]
  47. J Clin Exp Neuropsychol. 2004 Feb;26(1):31-42 [PMID: 14972692]
  48. Drug Alcohol Depend. 2016 May 1;162:72-8 [PMID: 26971229]
  49. Eur Neuropsychopharmacol. 2014 Nov;24(11):1793-7 [PMID: 25224107]
  50. Neurotox Res. 2020 Jan;37(1):67-76 [PMID: 31691188]
  51. Appl Neuropsychol Adult. 2018 May-Jun;25(3):231-236 [PMID: 28631987]
  52. J Addict Med. 2018 Mar/Apr;12(2):99-106 [PMID: 29194102]
  53. Alcohol Clin Exp Res. 2015 Nov;39(11):2249-60 [PMID: 26503070]
  54. Alcohol Clin Exp Res (Hoboken). 2024 Nov;48(11):2070-2078 [PMID: 39245727]
  55. Alcohol Clin Exp Res. 2010 Mar 1;34(3):443-50 [PMID: 20028356]
  56. Psychol Rep. 2002 Jun;90(3 Pt 1):858-60 [PMID: 12090519]
  57. Subst Use Misuse. 2022;57(9):1462-1469 [PMID: 35762149]
  58. J Alzheimers Dis. 2014;42(1):275-89 [PMID: 24844687]
  59. Med Care. 2006 Nov;44(11 Suppl 3):S69-77 [PMID: 17060838]
  60. Neuropsychol Rev. 2020 Sep;30(3):425-442 [PMID: 32691281]
  61. Addiction. 2017 Dec;112(12):2132-2143 [PMID: 28623859]

MeSH Term

Humans
Substance-Related Disorders
Neuropsychological Tests
Cognitive Dysfunction
Reproducibility of Results

Word Cloud

Created with Highcharts 10.0.0RBANSuseSUDdisorderpatientscognitivesystematicreviewsearchCognitivesubstanceimpairmentvaliditypatientgroupsdetectresearchusingstudiesarticlesalcoholmethamphetamineidentifiedevidenceprofilesreliabilityfactorstructureconstructcriterionBACKGROUND:deficitsprevalentamongaffecttreatmentretentionoutcomeRepeatableBatteryAssessmentNeuropsychologicalStatuswell-researchedinstrumentdiversepotentialserveeffectiveaccuratemethodidentifyingexaminesRBANS'abilityLimitationsknowledgeneeddiscussedMETHODS:conductedPsycINFOMedlineCochranedatabasesidentifyrelevantapplyingtimelimitsimposedSearchwordsdrugcommonspecifictypesdrugsegopiatescannabisRESULTS:23217foundeligibleincludedexaminedeitheropioidsresultspresentedformnarrativecangroupdifferenceshealthycontrolsfindingssomewhatinconsistentliteraturerevealedlittleinformationCONCLUSIONS:concerningusefulnesspopulationsscarceFutureinvestigaterepeatablebatteryassessmentneuropsychologicalstatusdisorders:AlcoholscreeningSubstance

Similar Articles

Cited By